

**Prescriber Information**

Prescriber Name:				MD	DO	NP	PA	NPI:
Office Contact:				Practice Name / Collaborating MD:				
Address:			City:		State:		Zip:	
Phone:		Fax:						

**Patient Information • PLEASE SEND COPY OF INSURANCE CARD**

Patients Name:		Last 4 Digits of SS#:		DOB: / /	Sex: M F	Weight:	Height:	Diabetic? Y N
Address:			City:		State:		Zip:	
Home Phone:		Work/Cell:		HIPAA Contact:			Emergency #:	
Interpreter Needed? Y N	Allergies: Y N <b>If Yes, list allergies:</b>							

**Insurance Information**

Primary Insurance:		Policy ID:	Group #:	BIN:	PCN:
Policyholder Name:			Policyholder DOB: / /		

**Dermatology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES**

ICD-10/Diagnosis Code:	Psoriasis Vulgaris (L40.0)	Other Psoriasis (L40.8)	Psoriasis unspecified (L40.9)	Psoriatic Arthritis (L40.5)	Hidradenitis Suppurativa (L73.2)	Chronic Urticaria (L50.8)
Atopic Dermatitis (L20.9)		TB/PDD Test Given: Y N	Date of Neg. Test: / /	HBV Positive? Y N <b>If Yes, is patent currently treated?</b> Y N		
Prior Treatment? Y N	BSA Affected (%):		Affected Areas: Palms Soles Head Neck Genitalia Other:			

**Gastroenterology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES**

ICD-10/Diagnosis Code:	K50.__(Crohn's Disease)	K51.__(Ulcerative Colitis)	Other:				
Date of Diagnosis: / /		Date of Negative TB Test: / /			Prior Treatment? Y N		

**Rheumatology • PLEASE SEND COPY OF MEDICAL AND PRESCRIPTION INSURANCE CARDS, PROGRESS NOTES AND LAB REPORTS, SUPPORTING DIAGNOSIS, CO-MORBIDITIES AND LAB VALUES**

ICD-10/Diagnosis Code:	M32.9 Active Systemic Lupus Erythematosus	M45.9 Ankylosing Spondylitis	M08.0 Juvenile Idiopathic Arthritis	L40.59 Psoriatic Arthritis	L40.54 Psoriatic Juvenile Arthritis
M06.9 Rheumatoid Arthritis		M45.A ____ Non-Radiographic Axial Spondyloarthritis		Other:	
Date of Diagnosis: / /		Date of Neg. TB Test: / /		Any prior treatment? Y N	

**Notes to Pharmacy**

**Prescription Information**

	Quantity/Dose	Sig	Refills
<b>ACTEMRA®</b> (tocilizumab)	Number of 80mg/4ml vials: _____ Number of 200mg/10ml vials: _____ Number of 400mg/20ml vials: _____	Infuse ____ mg IV over 60 minutes every 4 weeks Infuse ____ mg IV over 60 minutes every 2 weeks	
<b>BENLYSTA®</b> (belimumab)	Number of 120mg/5ml vials: _____ Number of 400mg/20ml vials: _____	<b>Starter Dose:</b> Infuse ____ mg IV over 1 hour at weeks 0, 2, and 4	<b>No Refills</b>
		<b>Maintenance Dose:</b> Infuse ____ mg IV over 1 hour once every 4 weeks	
<b>COSENTYX®</b> (secukinumab)	Number of 125mg/5ml vials: _____	<b>Starter Dose:</b> Infuse ____ mg at week 0 No starter dose	<b>No Refills</b>
	Number of 125mg/5ml vials: _____	<b>Maintenance Dose:</b> Infuse ____ mg every 4 weeks	
<b>ENTYVIO®</b> (vedolizumab)	2 vials (300mg each)	<b>Starter Dose:</b> Infuse 300mg IV over 30 minutes at weeks 0 and 2	<b>No Refills</b>
	1 vial (300mg)	<b>Maintenance Dose:</b> Infuse 300mg IV over 30 minutes once every 8 weeks beginning at week 6	
<b>OMVOH™</b> (mirikizumab-mrkz)	1 vial (300mg/15ml) 3 vials (300mg/15ml)	<b>UC Starter Dose:</b> Infuse 300mg IV at weeks 0, 4 and 8. Begin SQ maintenance dosing at week 12. <b>CD Starter Dose:</b> Infuse 900mg IV at weeks 0, 4 and 8. Begin SQ maintenance dosing at week 12.	<b>2 Refills</b>
<b>ORENCIA®</b> (abatacept)	Number of 250mg vials: _____	<b>Starter Dose:</b> Infuse ____ mg IV at weeks 0 and 2	<b>No Refills</b>
		<b>Maintenance Dose:</b> Infuse ____ mg IV at week 4 and every 4 weeks thereafter	

By signing this form and utilizing our services, you are authorizing Meijer and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber Signature	Date	Prescriber Signature	Date
----------------------	------	----------------------	------

Substitution Permitted

Dispense as Written

If brand is required, please write "DAW" in the box to the right.